We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic (HOLX) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
In the latest trading session, Hologic (HOLX - Free Report) closed at $74.06, marking a -1.41% move from the previous day. This move lagged the S&P 500's daily loss of 0.42%. Elsewhere, the Dow lost 0.56%, while the tech-heavy Nasdaq lost 0.08%.
Heading into today, shares of the medical device maker had lost 2.53% over the past month, lagging the Medical sector's gain of 1.89% and the S&P 500's gain of 1.02% in that time.
Hologic will be looking to display strength as it nears its next earnings release. In that report, analysts expect Hologic to post earnings of $0.85 per share. This would mark year-over-year growth of 3.66%. Meanwhile, our latest consensus estimate is calling for revenue of $941.83 million, down 1.2% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.92 per share and revenue of $4.03 billion. These totals would mark changes of -34.88% and -17.19%, respectively, from last year.
Any recent changes to analyst estimates for Hologic should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.05% lower within the past month. Hologic is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Hologic is holding a Forward P/E ratio of 19.16. This valuation marks a discount compared to its industry's average Forward P/E of 29.98.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 106, which puts it in the top 43% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hologic (HOLX) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Hologic (HOLX - Free Report) closed at $74.06, marking a -1.41% move from the previous day. This move lagged the S&P 500's daily loss of 0.42%. Elsewhere, the Dow lost 0.56%, while the tech-heavy Nasdaq lost 0.08%.
Heading into today, shares of the medical device maker had lost 2.53% over the past month, lagging the Medical sector's gain of 1.89% and the S&P 500's gain of 1.02% in that time.
Hologic will be looking to display strength as it nears its next earnings release. In that report, analysts expect Hologic to post earnings of $0.85 per share. This would mark year-over-year growth of 3.66%. Meanwhile, our latest consensus estimate is calling for revenue of $941.83 million, down 1.2% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.92 per share and revenue of $4.03 billion. These totals would mark changes of -34.88% and -17.19%, respectively, from last year.
Any recent changes to analyst estimates for Hologic should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.05% lower within the past month. Hologic is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Hologic is holding a Forward P/E ratio of 19.16. This valuation marks a discount compared to its industry's average Forward P/E of 29.98.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 106, which puts it in the top 43% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.